Specify a stock or a cryptocurrency in the search bar to get a summary
Castle Biosciences Inc
CSTLCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Address: 505 South Friendswood Drive, Friendswood, TX, United States, 77546
Analytics
WallStreet Target Price
33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CSTL
Dividend Analytics CSTL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CSTL
Stock Valuation CSTL
Financials CSTL
Results | 2019 | Dynamics |